Inventor · disambiguated record
Donald B. Kohn
Also filed as: KOHN DONALD · KOHN DONALD B
6 granted patents·17 pending applications·39 citations·filing 1994–2024
76Inventor score
Top patents by PatentIndex Score
23 records- 0174US12060566B2Self-inactivating lentiviral vector comprising a FOXP3 expression cassetteUNIV CALIFORNIA·Filed 2018·Granted Aug 13, 2024·1 cites·13 claims
- 0272US2024336935A1Self-inactivating lentiviral vector comprising a foxp3 expression cassetteUNIV CALIFORNIA·Filed 2024·Application pending·0 cites
- 0365US2025235480A1Vectors combining anti-sickling beta-as3-globin with anti bcel11a shrnamir to treat beta-hemoglobinopathiesUNIV CALIFORNIA·Filed 2023·Application pending·0 cites
- 0464US2025381295A1Lentiviral vectors expressing alpha-globin genes for gene therapy of alpha thalassemiaUNIV CALIFORNIA·Filed 2023·Application pending·0 cites
- 0563US2025144147A1Base editing and crispr/cas9 gene editing strategies to correct cd3 severe combined immunodeficiency in hematopoietic stem cellsUNIV CALIFORNIA·Filed 2023·Application pending·0 cites
- 0658US2024200100A1Packaging cells with targeted gene knockouts that improve retroviral vector titersUNIV CALIFORNIA·Filed 2022·Application pending·0 cites
- 0755US5707865ARetroviral vectors for expression in embryonic cellsFiled 1994·Granted Jan 13, 1998·26 cites·12 claims
- 0855US2024082427A1Method of designing highly regulated lentiviral vectors possesing strict endogenous regulationUNIV CALIFORNIA·Filed 2022·Application pending·0 cites
- 0954US2022389454A1Lentiviral vectors in hematopoietic stem cells to treat recombination-activating gene 1 (rag1) severe combined immunodeficiency (scid)UNIV CALIFORNIA·Filed 2020·Application pending·0 cites
- 1052US2024299586A1Novel aav serotypes derived from a library screenUNIV CALIFORNIA·Filed 2022·Application pending·0 cites
- 1152US2022378937A1Lentiviral vectors in hematopoietic stem cells to treat x-linked chronic granulomatous diseaseUNIV CALIFORNIA·Filed 2020·Application pending·0 cites
- 1251US2022170045A1Augmentations to lentiviral vectors (cclc-mgata/ank-core lcr-beta-as3-fb) to increase expressionUNIV CALIFORNIA·Filed 2020·Application pending·0 cites
- 1350US2022136007A1Optimized lentiviral vector compromising minimal enhancer elements for stem cell gene therapy of hemoglobinopathiesUNIV CALIFORNIA·Filed 2020·Application pending·0 cites
- 1449US2022387528A1Lentiviral vectors in hematopoietic stem cells to treat wiskott-aldrich syndrome (was)UNIV CALIFORNIA·Filed 2020·Application pending·0 cites
- 1546US11976293B2Optimized lentiviral vector for stem cell gene therapy of hemoglobinopathiesUNIV CALIFORNIA·Filed 2017·Granted May 7, 2024·0 cites·12 claims
- 1646US2015224209A1Lentiviral vector for stem cell gene therapy of sickle cell diseaseKOHN DONALD B·Filed 2013·Application pending·0 cites
- 1746US2017157270A1Lentiviral vector for stem cell gene therapy of sickle cell diseaseUNIV CALIFORNIA·Filed 2016·Application pending·0 cites
- 1845US12492411B2Gene editing of monogenic disorders in human hematopoietic stem cells—correction of X-linked agammaglobulinemia (XLA)UNIV CALIFORNIA·Filed 2019·Granted Dec 9, 2025·0 cites·13 claims
- 1942US6984379B1Gene therapy by administration of genetically engineered CD34+ cells obtained from cord bloodUS HEALTH·Filed 1994·Granted Jan 10, 2006·12 cites·16 claims
- 2042US2021155927A1Methods for treating sickle cell diseaseUNIV CALIFORNIA·Filed 2019·Application pending·0 cites
- 2139US2019249172A1Methods and compositions for gene editing in stem cellsUNIV CALIFORNIA·Filed 2017·Application pending·0 cites
- 2235US10583180B2Method for treating adenosine deaminase severe combined imunodeficiencyUCL BUSINESS PLC·Filed 2016·Granted Mar 10, 2020·0 cites·23 claims
- 2333US2018185415A1Retroviral vectors containing a reverse orientation human ubiquitin c promoterUNIV CALIFORNIA·Filed 2016·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →